BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21554264)

  • 1. Advances in the prognostication and management of advanced MDS in children.
    Hasle H; Niemeyer CM
    Br J Haematol; 2011 Jul; 154(2):185-95. PubMed ID: 21554264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndrome in children and adolescents.
    Niemeyer CM; Baumann I
    Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study.
    Strahm B; Nöllke P; Zecca M; Korthof ET; Bierings M; Furlan I; Sedlacek P; Chybicka A; Schmugge M; Bordon V; Peters C; O'Marcaigh A; de Heredia CD; Bergstraesser E; Moerloose BD; van den Heuvel-Eibrink MM; Starý J; Trebo M; Wojcik D; Niemeyer CM; Locatelli F;
    Leukemia; 2011 Mar; 25(3):455-62. PubMed ID: 21212791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
    Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
    Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T; Yasuyama M; Kawauchi K
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
    Estey E; Trujillo JM; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich EJ; Stass S
    Hematol Pathol; 1992; 6(1):43-8. PubMed ID: 1601822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytogenetic study of 93 myelodysplastic syndromes].
    Solé F; Woessner S; Florensa L; Pérez-Losada A; Acín P; Besses C; García-Eroles L; Sans-Sabrafen J
    Med Clin (Barc); 1998 Jan; 110(3):94-8. PubMed ID: 9534140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
    Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
    J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation.
    Choi SW; Boxer LA; Pulsipher MA; Roulston D; Hutchinson RJ; Yanik GA; Cooke KR; Ferrara JL; Levine JE
    Bone Marrow Transplant; 2005 Mar; 35(5):473-7. PubMed ID: 15640815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
    Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
    Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
    Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
    Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
    Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS).
    Hasle H; Aricò M; Basso G; Biondi A; Cantù Rajnoldi A; Creutzig U; Fenu S; Fonatsch C; Haas OA; Harbott J; Kardos G; Kerndrup G; Mann G; Niemeyer CM; Ptoszkova H; Ritter J; Slater R; Starý J; Stollmann-Gibbels B; Testi AM; van Wering ER; Zimmermann M
    Leukemia; 1999 Mar; 13(3):376-85. PubMed ID: 10086728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
    Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
    Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
    Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.